Lexicon Financial Statements From 2010 to 2024

LXRX Stock  USD 2.19  0.21  10.61%   
Lexicon Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Lexicon Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexicon Pharmaceuticals financial statements helps investors assess Lexicon Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexicon Pharmaceuticals' valuation are summarized below:
Gross Profit
-52.7 M
Market Capitalization
487.5 M
Enterprise Value Revenue
799.2203
Revenue
1.2 M
Earnings Share
(0.80)
We have found one hundred twenty available fundamental ratios for Lexicon Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexicon Pharmaceuticals last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 12.2 M or Total Revenue of 1.1 M, as well as many exotic indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0174 or Operating Cycle of 2 K. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Lexicon Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Lexicon Pharmaceuticals Technical models . Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Lexicon Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets326.8 M229.4 M328.7 M
Pretty Stable
Short and Long Term Debt Total75.1 M104.8 M92.4 M
Pretty Stable
Total Current Liabilities48.4 M31.5 M53.6 M
Very volatile
Property Plant And Equipment Net7.1 M7.5 M16.5 M
Slightly volatile
Accounts Payable13.3 M14.4 M16.7 M
Very volatile
Cash21.3 M22.5 M175.4 M
Slightly volatile
Non Current Assets Total104.9 M52.9 M92.8 M
Slightly volatile
Non Currrent Assets Other786.6 K828 K1.8 M
Pretty Stable
Cash And Short Term Investments206.8 M170 M223.1 M
Pretty Stable
Net Receivables959.5 KM5.7 M
Very volatile
Common Stock Shares Outstanding232.2 M221.1 M112.2 M
Slightly volatile
Short Term Investments137 M147.6 M146.5 M
Very volatile
Non Current Liabilities Total100.6 M104.8 M123.7 M
Very volatile
Other Current Assets6.8 M5.1 M5.8 M
Pretty Stable
Total Liabilities149 M136.3 M177.3 M
Very volatile
Property Plant And Equipment Gross11 M11.6 M18.1 M
Slightly volatile
Total Current Assets221.8 M176.5 M235.9 M
Pretty Stable
Short Term Debt1.4 M1.5 MM
Slightly volatile
Long Term Debt75.6 M55.9 M88.7 M
Pretty Stable
Common Stock Total Equity212.7 K217.3 K247.9 K
Slightly volatile
Property Plant Equipment1.8 M1.9 M16.1 M
Slightly volatile
Other Liabilities43.1 M26.8 M45.3 M
Pretty Stable
Good Will40.9 M51.2 M43.5 M
Slightly volatile
Intangible Assets41.5 M22.7 M38.1 M
Slightly volatile
Long Term Debt Total282.8 M269.3 M155.3 M
Slightly volatile
Capital Surpluse1.5 BB1.4 B
Slightly volatile
Deferred Long Term Liabilities52.6 M34.1 M41.4 M
Very volatile
Non Current Liabilities Other4.6 M4.9 M15.5 M
Slightly volatile
Short and Long Term Debt8.7 M10.5 M13.3 M
Slightly volatile
Net Invested Capital176.8 M149.1 M249.1 M
Slightly volatile
Net Working Capital120.3 M105.9 M167.6 M
Slightly volatile
Capital Stock152.5 K217.3 K127.4 K
Slightly volatile
Capital Lease Obligations8.1 M7.7 M2.5 M
Slightly volatile

Lexicon Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.4 M4.3 M
Very volatile
Total Revenue1.1 M1.2 M49.9 M
Very volatile
Other Operating Expenses145.3 M173 M136.1 M
Slightly volatile
Research Development97.4 M58.9 M93.9 M
Very volatile
Total Operating Expenses145.1 M172.9 M135.6 M
Slightly volatile
Selling General Administrative102.6 M97.7 M41.6 M
Slightly volatile
Non Operating Income Net Other1.9 M1.8 M1.6 M
Slightly volatile
Interest Income6.5 M6.2 M4.6 M
Slightly volatile
Reconciled Depreciation484.5 K510 K2.6 M
Slightly volatile
Extraordinary Items3.2 M3.6 M3.9 M
Slightly volatile

Lexicon Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.6 M46.3 M78.2 M
Very volatile
Depreciation526.3 K554 K2.3 M
Slightly volatile
Capital Expenditures446.5 K470 K845.6 K
Slightly volatile
End Period Cash Flow21.3 M22.5 M73.4 M
Pretty Stable
Stock Based Compensation9.7 M14.3 M9.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio209281435
Slightly volatile
Dividend Yield0.01740.01830.159
Pretty Stable
Operating CycleK1.9 K558
Slightly volatile
Inventory Turnover0.240.260.6841
Slightly volatile
Cash Per Share0.730.76893.669
Slightly volatile
Quick Ratio8.125.42187.7648
Slightly volatile
Net Income Per E B T0.540.910.9676
Slightly volatile
Cash Ratio0.680.71214.046
Slightly volatile
Days Of Inventory Outstanding1.5 K1.5 K697
Slightly volatile
Days Of Sales Outstanding322306121
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.431.00291.0617
Very volatile
Current Ratio7.025.59655.692
Pretty Stable
Fixed Asset Turnover0.150.16039.7462
Pretty Stable
Debt Ratio0.480.45670.3171
Pretty Stable
Price Sales Ratio209281435
Slightly volatile
Receivables Turnover1.131.192120.7065
Very volatile
Asset Turnover0.0050.00520.132
Very volatile

Lexicon Fundamental Market Drivers

Cash And Short Term Investments170 M

Lexicon Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lexicon Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lexicon Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Lexicon Pharmaceuticals investors use historical funamental indicators, such as Lexicon Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lexicon Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Lexicon Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lexicon Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lexicon Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue32.4 M20 M
Total Revenue1.2 M1.1 M
Cost Of Revenue85 K80.8 K
Ebit Per Revenue(142.65)(135.52)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lexicon Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lexicon Pharmaceuticals' short interest history, or implied volatility extrapolated from Lexicon Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Directory
Find actively traded commodities issued by global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.80)
Revenue Per Share
0.005
Quarterly Revenue Growth
24.071
Return On Assets
(0.51)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.